Trelagliptin-13C,d3
Product Specifications
UNSPSC Description
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin[1]. Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM)[2].
Target Antigen
Dipeptidyl Peptidase; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Metabolic Enzyme/Protease;Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Smiles
N#CC1=CC=C(F)C=C1CN(C(N2[13C]([2H])([2H])[2H])=O)C(N3C[C@H](N)CCC3)=CC2=O
Molecular Weight
361.39
References & Citations
[1]Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605.|[2]Charles E Grimshaw, et al. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS One. 2016 Jun 21;11(6):e0157509.|[3]Shiliang Li, et al. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem. 2019 Mar 14;62(5):2348-2361.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
CAS Number
2707203-34-5
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
